ReviewFrontiers in immunology2025
Research progress on pyroptosis regulated by mesenchymal stem cell-derived exosomes.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis is a newly discovered form of inflammatory programmed cell death, which is frequently involved in the occurrence and development of various diseases. The primary mechanism underlying pyroptosis is the formation of membrane pores mediated by activated pyroptosis-related proteins. The expression levels of these pyroptosis-related proteins serve as crucial biomarkers for assessing the degree of pyroptosis. Modulating pyroptosis can alleviate tissue and organ damage in diseases and promote tissue and organ repair. Therefore, regulating pyroptosis is considered a potential therapeutic strategy. In recent years, mesenchymal stem cell-derived exosomes (MSC-Exos) have emerged as a novel therapeutic tool for pyroptosis due to their carrier properties. MSC-Exos can mitigate tissue damage in various diseases by regulating pyroptosis, thus emerging as strong candidates for disease treatment. Owing to their multifunctionality, MSC-Exos exert different effects by mediating different pathways in the treatment of various diseases. This review summarizes the mechanisms of pyroptosis and the research progress on MSC-Exos-regulated pyroptosis and outlines the existing challenges for the clinical translation of MSC-Exos. Collectively, MSC-Exos can not only precisely regulate the pyroptosis process but also provide new perspectives and approaches for future disease treatment. Therefore, MSC-Exos possess substantial potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.